Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CEO Amy Burroughs sold 14,583 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $46.71, for a total value of $681,171.93. Following the sale, the chief executive officer owned 288,976 shares in the company, valued at $13,498,068.96. The trade was a 4.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Terns Pharmaceuticals Stock Up 0.9%
Terns Pharmaceuticals stock opened at $46.47 on Wednesday. The stock has a 50-day simple moving average of $39.06 and a 200 day simple moving average of $26.93. Terns Pharmaceuticals, Inc. has a 12-month low of $1.87 and a 12-month high of $48.26. The stock has a market capitalization of $4.82 billion, a price-to-earnings ratio of -45.12 and a beta of -0.31.
Analyst Ratings Changes
A number of brokerages have weighed in on TERN. Oppenheimer boosted their target price on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 9th. Barclays raised their price target on shares of Terns Pharmaceuticals from $36.00 to $56.00 and gave the company an "overweight" rating in a report on Tuesday, December 9th. Citizens Jmp boosted their price objective on shares of Terns Pharmaceuticals from $35.00 to $57.00 and gave the stock a "market outperform" rating in a research report on Thursday, December 11th. Jefferies Financial Group reaffirmed a "buy" rating and set a $70.00 price objective on shares of Terns Pharmaceuticals in a report on Wednesday, December 10th. Finally, Mizuho increased their price objective on Terns Pharmaceuticals from $33.00 to $54.00 and gave the company an "outperform" rating in a research report on Tuesday, December 9th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $58.11.
Read Our Latest Stock Report on Terns Pharmaceuticals
Institutional Trading of Terns Pharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in the business. AlphaQuest LLC grew its holdings in Terns Pharmaceuticals by 9,088,200.0% during the third quarter. AlphaQuest LLC now owns 90,883 shares of the company's stock valued at $683,000 after purchasing an additional 90,882 shares during the period. Dynamic Technology Lab Private Ltd raised its stake in shares of Terns Pharmaceuticals by 237.2% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 66,576 shares of the company's stock valued at $500,000 after purchasing an additional 46,831 shares during the period. DLD Asset Management LP acquired a new stake in Terns Pharmaceuticals in the 2nd quarter valued at approximately $138,000. Commodore Capital LP bought a new stake in shares of Terns Pharmaceuticals in the third quarter worth $42,807,000. Finally, Franklin Resources Inc. acquired a new position in Terns Pharmaceuticals during the second quarter worth $4,765,000. Institutional investors own 98.26% of the company's stock.
About Terns Pharmaceuticals
(
Get Free Report)
Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company's research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.
The company's pipeline features several candidates in various stages of preclinical and clinical evaluation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
